Metraipolis › archive › dc_60c61058366e

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study — Europe PMC PMID:41560662

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41560662
DOI
10.1080/07853890.2026.2617767
License (as archived)
solo-consultazione
Archived
2026-11-06T15:58:26.744Z
SHA-256 of the archived text
9d9f449b096304430f3b817ca2766a89516a339187ed7b0024d7a9e22dd7b275
Stable URL of this page
https://metraipolis.com/documento/dc_60c61058366e

How to cite

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study — Europe PMC PMID:41560662 — Europe PMC (en), https://europepmc.org/article/MED/41560662 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_60c61058366e (Metraipolis archive dc_60c61058366e, sha256 9d9f449b096304430f3b817ca2766a89516a339187ed7b0024d7a9e22dd7b275)
BibTeX
@misc{dc60c61058366e,
  title = {Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study — Europe PMC PMID:41560662},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41560662},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_60c61058366e; sha256 9d9f449b096304430f3b817ca2766a89516a339187ed7b0024d7a9e22dd7b275},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41560662. Agents can read the archived copy with the MCP tool read_document.